Teresa Helsten

Title(s)	Clinical Professor, Medicine
School	Vc-health Sciences-schools
Address	9500 Gilman Drive # La Jolla CA 92093
vCard	Download vCard

Overview

Research Interests
Dr. Helsten focuses first and foremost on providing excellent care for breast cancer patients. She provides neoadjuvant, adjuvant, and metastatic treatments, including endocrine therapy, chemotherapy, and targeted therapies. She actively enrolls patients to clinical trials.

Dr. Helsten’s research is primarily focused on clinical trials chosen to bring the most cutting edge care to her patients. She runs several clinical trials and enrolls patients to these and cooperative group and investigator initiated trials at UCSD. She is a coinvestigator of the groundbreaking I-SPY 2 study (www.ispy2.org). She is actively engaged in the design and implementation of translational research projects in breast cancer. FGFR inhibitors are of particular interest.

Education and Training
BS - Chemistry, Massachusetts Institute of Technology - 1990
MD - University of California, Davis - 1998
Resident - Harbor-UCLA Medical Center - 1998-2001
Chief Resident - Harbor-UCLA Medical Center - 2001-2002
Oncology Fellowship - UC San Diego Medical Center - 2002-2005

Interests

Medical oncology, Breast cancer, Clinical Trials, FGFR, Fibroblast growth factor, Fibroblast growth factor receptor

Websites

	Divisions of Hematology-Oncology and Bone Marrow Transplantation
	Clinical Profile

ORNG Applications

Clinical Trials

Bibliographic

Publications

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.

Altmetrics Details

PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.

The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing. Clin Cancer Res. 2016 Jan 01; 22(1):259-67. Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. PMID: 26373574.

View in: PubMed Mentions: 156 Fields:
Neo Neoplasms
Translation:Humans
Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications. Cancer Metastasis Rev. 2015 Sep; 34(3):479-96. Helsten T, Schwaederle M, Kurzrock R. PMID: 26224133.

View in: PubMed Mentions: 37 Fields:
Neo Neoplasms
Translation:Humans Cells
Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics. . 2015; 14(13):2121-8. Parish A, Schwaederle M, Daniels G, Piccioni D, Fanta P, Schwab R, Shimabukuro K, Parker BA, Helsten T, Kurzrock R. PMID: 25950492.

View in: PubMed Mentions:
Differences in regulation of Drosophila and vertebrate integrin affinity by talin. Mol Biol Cell. 2008 Aug; 19(8):3589-98. Helsten TL, Bunch TA, Kato H, Yamanouchi J, Choi SH, Jannuzi AL, Féral CC, Ginsberg MH, Brower DL, Shattil SJ. PMID: 18508915.

View in: PubMed Mentions: 10 Fields:
Cel Cell Biology Mol Molecular Biology
Translation:Animals Cells